Therapy News and Research

RSS

Noninvasive ventilation can shorten intubation time and may reduce risk of post-extubation ARF

Noninvasive ventilation (NIV) used as a weaning technique for mechanically ventilated patients can shorten intubation time and may reduce the risk of post-extubation acute respiratory failure (ARF), according to French researchers.

13 Jun 2011

Incyte announces additional results from ruxolitinib Phase III trial on myelofibrosis

Incyte Corporation announced today additional symptom improvement and quality of life (QoL) results from COMFORT-I, a randomized, double-blinded, placebo-controlled Phase III trial of Incyte's JAK1 and JAK2 inhibitor, ruxolitinib, in patients with myelofibrosis (MF).

13 Jun 2011

Seattle Genetics, Millennium ADCETRIS phase I trial data on Hodgkin lymphoma presented at EHA

Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited and Seattle Genetics, Inc., announced today that data on ADCETRIS (brentuximab vedotin) in relapsed or refractory Hodgkin lymphoma patients were featured in an oral presentation at the 16th Congress of the European Hematology Association (EHA) in London.

13 Jun 2011

Final data from Alexion's Soliris Phase 2 studies on aHUS presented at EHA 2011

Alexion Pharmaceuticals, Inc. today announced the presentation of final data from the two Phase 2 studies of Soliris as a treatment for patients with atypical hemolytic uremic syndrome.

13 Jun 2011

Hyperthermia prevents repair of tumor cells

BSD Medical Corporation, a leading provider of medical systems that utilize heat therapy to treat cancer, announced today that a study published in the Proceedings of the National Academy of Sciences demonstrated that hyperthermia can be a powerful tool to inhibit the ability of cancer cells to repair the DNA damage caused by radiation or chemotherapy.

10 Jun 2011

State news: Mass. immigrant care; Pension benefit changes in Calif. cities

Thousands of legal immigrants may have to wait weeks longer to find out whether the state's highest court will order Massachusetts to restore their full health insurance benefits. Massachusetts Supreme Judicial Court Associate Justice Robert J. Cordy today ordered lawyers for the state to file their motions by June 23.

10 Jun 2011

Larger trial study needed to decide fate of niacin

Niaspan is a cholesterol drug manufactured by Abbott Laboratories. Doctors have customarily prescribed Niacin to raise levels of HDL ("good" cholesterol) in patients taking a statin pill that is successfully lowering their LDL ("bad" cholesterol).

10 Jun 2011

Blinatumomab phase 2 trial results on acute lymphoblastic leukemia to be presented at EHA 2011

Data to be presented tomorrow at the 16th Annual Meeting of the European Hematology Association (EHA) in London, UK, show that Micromet's blinatumomab produced a high complete remission rate in adult patients with acute lymphoblastic leukemia (ALL) who had relapsed following treatment with standard therapy.

10 Jun 2011

Study links mutations in essential genes with orphan diseases

Mutations in genes essential to survival are behind so-called orphan diseases, explaining in part why these diseases are rare and often deadly, according to a study appearing in The American Journal of Human Genetics.

10 Jun 2011

FDA accepts ZIOPHARM's IND for ZIN ATI-001 to treat melanoma

ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced today that the U.S. Food & Drug Administration has accepted the Company's investigational new drug application to begin clinical study of ZIN ATI-001, a novel DNA-based therapeutic candidate also known as Ad-RTS-IL-12 + AL, in oncology.

10 Jun 2011

Inspire's Stimulation Therapy for Apnea Reduction trial reaches milestones

Inspire Medical Systems, the leading developer of neurostimulation therapies for the treatment of obstructive sleep apnea (OSA), announced today The STAR trial, evaluating both the safety and effectiveness of Inspire Upper Airway Stimulation (UAS) therapy, is currently underway at 9 leading medical centers across the United States and at 4 sites in Europe.

10 Jun 2011

Scientists uncover new role for key cancer protein

Scientists at Dana-Farber Cancer Institute have uncovered a new role for a key cancer protein, a finding that could pave the way for more-effective radiation treatment of a variety of tumors.

10 Jun 2011

Study identifies sharp rise in Parkinson's prevalence in Israel from 2000 to 2007

In a new study published today in the inaugural issue of the Journal of Parkinson's Disease, Israeli researchers report that by tracking pharmacy purchases of anti-Parkinson drugs they could estimate the number of Parkinson's disease (PD) cases in a large population.

10 Jun 2011

New bariatric bed

Twenty-percent of the adult U.S. population is obese, including approximately five percent that are considered morbidly obese. The direct health issues, related complications and safety challenges affecting this population are far reaching and well documented. VitalGo, Inc., a provider of advanced technology-based solutions for medical staff safety, patient safety and home care, has announced the immediate availability of the new bariatric version of its Total Lift Bed™ (TLB) which addresses a wide variety of care, treatment and safety issues for patients weighing up to 1,000 lbs.

9 Jun 2011

Abbott reports positive interim results from LCIG Phase III open-label study for advanced Parkinson's disease

Interim efficacy and safety results from a long-term, 54-week, Phase III open-label study of Abbott's investigational treatment for advanced Parkinson's disease showed that patients treated with levodopa-carbidopa intestinal gel (LCIG) for 12 weeks reported a decrease in "off" time and an increase in "on" time without troublesome dyskinesias.

9 Jun 2011

Promising results from VX-770 and VX-809 Phase 2 study for cystic fibrosis

Vertex Pharmaceuticals Incorporated and the Cystic Fibrosis Foundation today announced promising results from an ongoing Phase 2 study evaluating combinations of VX-770 and VX-809, potential medicines designed to treat the defective protein that causes cystic fibrosis.

9 Jun 2011

Respira introduces breakthrough Dry Powder Inhaler

Respira Therapeutics, a product development company focused on inhaled therapeutics to improve patients' lives, introduces the company's Dry Powder Inhaler (DPI) as a breakthrough solution for the pharmaceutical industry. Based on proprietary drug engine technology (DET), Respira Therapeutics' DPI significantly improves therapeutic performance and enables addressing the unmet medical needs of patients with severe respiratory diseases.

9 Jun 2011

ASI announces successful completion of $10 million round of financing

Access Scientific, Inc. (ASI) today announced the successful completion of a $10 million round of financing. The round was led by CAC and further supported by the company's previous institutional investors.

9 Jun 2011

Make antiretroviral therapy 'cornerstone' of HIV prevention

Ahead of the U.N. High Level Meeting on AIDS, AVAC: Global Advocacy for HIV Prevention and multiple signatories in a statement call on governments, advocates and researchers to act on the evidence from HPTN 052 and make antiretroviral therapy a cornerstone of the set of proven strategies we have to prevent and treat HIV.

9 Jun 2011

PDL revises revenue guidance for second quarter 2011 to $122M

PDL BioPharma, Inc. (PDL) today revised its guidance for the second quarter ending June 30, 2011, to approximately $122 million, as compared with actual results of $120 million for the second quarter of 2010, an anticipated one percent year-over-year increase.

9 Jun 2011